LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of “Moderate Buy” by Brokerages

Shares of LifeMD, Inc. (NASDAQ:LFMD) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $11.57.

LFMD has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of LifeMD in a report on Monday, November 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. Mizuho initiated coverage on shares of LifeMD in a report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 price target for the company. Finally, Lake Street Capital assumed coverage on LifeMD in a report on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price objective on the stock.

Insider Buying and Selling

In related news, CEO Justin Schreiber sold 25,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.52, for a total value of $163,000.00. Following the sale, the chief executive officer now owns 2,728,715 shares in the company, valued at approximately $17,791,221.80. The trade was a 0.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.97% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LifeMD

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Calamos Advisors LLC purchased a new position in shares of LifeMD in the second quarter valued at approximately $394,000. Bank of New York Mellon Corp grew its stake in shares of LifeMD by 63.6% in the second quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock worth $1,609,000 after acquiring an additional 91,183 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of LifeMD during the second quarter worth $326,000. Los Angeles Capital Management LLC acquired a new stake in shares of LifeMD in the second quarter valued at $88,000. Finally, X Square Capital LLC purchased a new position in LifeMD in the second quarter valued at $509,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

LifeMD Trading Up 2.9 %

Shares of LifeMD stock opened at $5.04 on Friday. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78. The stock’s 50 day simple moving average is $5.38 and its 200-day simple moving average is $5.80. The stock has a market cap of $218.29 million, a P/E ratio of -7.88 and a beta of 1.38. LifeMD has a 1-year low of $3.99 and a 1-year high of $12.88.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.